Search by Drug Name
A B C D E F G H I J K L M N O P Q R S T U V W X Y ZClinical Trials for LORLATINIB
- Lorlatinib as the First-line Treatment in China Advanced ALK+ NSCLC
- Lorlatinib in Combination With Chemotherapy in Participants With Metastatic Anaplastic Lymphoma Kinase Positive (ALK+) Non-small Cell Lung Cancer (NSCLC) Who Progressed on Single-agent Lorlatinib
- Induction Lorlatinib in Stage III Non-small Cell Lung Cancer
- A Study of NVL-655 in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Activating ALK Mutation (ALKOVE-1)
- A Study of Lorlatinib in Subjects With ROS1-Positive Non-Small Cell Lung Cancer
- Study to Evaluate the Effect of Hepatic Impairment on the Pharmacokinetics and Safety of Lorlatinib
- Personalized DC Vaccines in Non Small Cell Lung Cancer
- Lorlatinib Continuation Study
- Strata PATH™ (Precision Indications for Approved Therapies)
- PF-07284892 in Participants With Advanced Solid Tumors
- Lorlatinib After Failure of First-line TKI in Patients With Advanced ROS1-positive NSCLC (ALBATROS)
- Lorlatinib in ALK Inhibitor Treated Unresectable Advanced/Recurrent ALK-Positive Non Small Cell Lung Cancer Patients in India
- Temodar Plus Tyrosine Kinase Inhibitors for Progressive CNS Disease
- Study of Lorlatinib In Participants With Anaplastic Lymphoma Kinase (ALK) -Positive NSCLC
- ProTarget - A Danish Nationwide Clinical Trial on Targeted Cancer Treatment Based on Genomic Profiling
- Lorlatinib Combinations in Lung Cancer
- Activity of Lorlatinib Based on ALK Resistance Mutations Detected on Blood in ALK Positive NSCLC Patients
- Lorlatinib After Failure of First-line Second-generation ALK Kinase Inhibitor in Patients With Advanced ALK-positive Non-small Cell Lung Cancer
- Effect of Multiple Doses of Modafinil on the Pharmacokinetics of Single Dose Lorlatinib in Healthy Participants
- A Study of Lorlatinib in ALK Inhibitor-Treated ALK-Positive NSCLC in China
- Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial
- Targeted Treatment for ALK Positive Patients Who Have Previously Been Treated for Non-squamous Non-small Cell Lung Cancer
- Hepatic Impairment Study for Lorlatinib in Cancer Patients
- Study of Lorlatinib in ROS1 Rearranged NSCLC
- Lorlatinib Renal Impairment Study
- A Study of Oral Lorlatinib in Patients With Relapsed ALK Positive Lymphoma
- PF-06463922 for Crizotinib Pretreated ROS1 Positive Non-small-cell Lung Cancer
- Single-dose Study of [14C]Lorlatinib (PF-06463922) Metabolism In Healthy Male Volunteers
- NANT 2015-02: A Phase 1 Study of Lorlatinib (PF-06463922)
- A Study Of Lorlatinib Versus Crizotinib In First Line Treatment Of Patients With ALK-Positive NSCLC
- A Study of Lorlatinib in Advanced ALK and ROS1 Rearranged Lung Cancer With CNS Metastasis in the Absence of Measurable Extracranial Lesions
- The Drug Rediscovery Protocol (DRUP Trial)
- A Study To Evaluate The Effect Of Itraconazole On Pharmacokinetics Of PF-06463922 In Healthy Volunteers
- A Study To Evaluate The Effect Of Rifampin On Pharmacokinetics Of PF-06463922 In Healthy Volunteers
Clinical trials list
click for details